close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.42 -1.03 (-2.13%)
Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
News headline image
Compounded GLP-1s And Competition Force Novo Nordisk To Slash Outlook ↗
Novo Nordisk reported Q2 sales of $11.7 billion, missing consensus. Sales increased by 13% in Danish kroner, driven by GLP-1 diabetes and obesity care sales. 
Via Benzinga
News headline image
Bryan Johnson Spent Millions To Be 18 Again—Says Novo Nordisk's Ozempic Anti-Aging Hype Is Misleading: 'Data Is Not There' ↗
Tech entrepreneur Bryan Johnson refutes claims that Novo Nordisk AS's Ozempic demonstrates anti-aging properties. 
Via Benzinga
News headline image
Novo Nordisk Edges Up Premarket As Q2 Wegovy Sales Defy Copycat Threats: Retail Stays Bullish Amid Tariff Pressure ↗
The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance. 
Via Stocktwits
Topics Government World Trade
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
US Market Under Pressure: Amazon, Eastman Chemical, and Hims & Hers Among Top Losers
The U.S. stock market experienced a turbulent start to August 2025, marked by significant declines for several prominent companies. This downturn, following a volatile end to July, has left investors... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Novo Nordisk Stock Is Down Again Today ↗
Are you brave enough to catch this falling knife? 
Via The Motley Fool
News headline image
What's Going On With Novo Nordisk Stock? ↗
Management pointed to competitors gaining market share in key product categories. 
Via The Motley Fool
News headline image
Novo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny Side ↗
UBS downgraded Novo Nordisk to ‘Neutral’ from ‘Buy’ with a price target of DKK 340, down from DKK 600. 
Via Stocktwits
News headline image
Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance ↗
The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug. 
Via Investor's Business Daily
News headline image
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Novo Nordisk Stock Sinks—But Is a Bottom Finally In? ↗
Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings 
Via MarketBeat
News headline image
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data ↗
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose. 
Via Benzinga
News headline image
Dollar's Worst Start Since 1970s Could Dent European Corporate Profits ↗
 
Via Benzinga
News headline image
Massive News for Novo Nordisk Stock Investors! ↗
Management told investors to expect slower sales and profit growth in 2025. 
Via The Motley Fool
News headline image
Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On? ↗
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations. 
Via Benzinga
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A High-Quality Dividend Stock with Strong Growth and Stability ↗
NVO offers dividend investors a strong 3.62% yield, 16.56% growth, and high profitability, backed by solid financial health and growth potential. 
Via Chartmill
News headline image
IBD 50's Hims & Hers Plummets 9% On Second-Quarter Sales Miss ↗
The company reiterated its sales outlook for the year, despite coming in with lighter-than-expected second-quarter sales. 
Via Investor's Business Daily
Topics ETFs Earnings
News headline image
This Biotech Stock Could Soar on Upcoming Clinical Data ↗
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
News headline image
Stock Market Today: US Stocks Likely To Open Higher Despite Weak Jobs Report—Palantir, Vertex Pharma In Focus ↗
US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics. 
Via Benzinga
News headline image
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts. 
Via Benzinga
News headline image
Why Is Novo Nordisk Stock Crashing, and Is It a Buying Opportunity? ↗
Competition from all sides is causing Novo Nordisk to revise its expectations for 2025. 
Via The Motley Fool
News headline image
Benzinga Bulls And Bears: Celestica, Carvana, Novo Nordisk — And Fed Holds Rates Despite Trump Pressure ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Topics Economy Government
News headline image
Why Eli Lilly Stock Topped the Market Today ↗
Zepbound could benefit handsomely if an apparently planned government program is implemented. 
Via The Motley Fool
Topics Government
News headline image
Why Novo Nordisk Stock Bumped Higher on Friday ↗
There might be a new way for certain users to defray their costs for obesity treatments. 
Via The Motley Fool
Topics Government
News headline image
Will Hims & Hers Fall Along With Novo Nordisk? ↗
Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming. 
Via MarketBeat
News headline image
Why Novo Nordisk Stock Imploded This Week ↗
Could this be a buying opportunity amid historically low valuations? 
Via The Motley Fool
News headline image
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare ↗
The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro, and Zepbound for patients... 
Via Stocktwits
Topics Government
News headline image
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients ↗
FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes. 
Via Benzinga
News headline image
Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients ↗
The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy under Medicare and Medicaid programs. 
Via Benzinga
Topics Government
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today